Reuters logo
BRIEF-OSE Immunotherapeutics announces temporary pause of patient accrual in phase 3 trial of Tedopi in advanced lung cancer
2017年6月23日 / 晚上7点16分 / 5 个月前

BRIEF-OSE Immunotherapeutics announces temporary pause of patient accrual in phase 3 trial of Tedopi in advanced lung cancer

June 23 (Reuters) - OSE Immunotherapeutics SA:

* OSE Immunotherapeutics announces temporary pause of patient accrual while continuing treatment for patients already enrolled in phase 3 clinical trial of Tedopi in advanced lung cancer

* Decided to halt temporarily patient enrollment, but to continue treatment of patients already enrolled in this clinical trial

* Safety profile observed in experimental treatment group is consistent with one observed in previous clinical trials of Tedopi

* Decided to halt temporarily patient enrollment due to an emerging benefit/risk balance of experimental treatment

* Following further review of more patients’ data, a decision will be made for trial continuation

* Following review, decision to be made for trial continuation or possible amendment to include specific sub-groups of patients Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below